Cue Biopharma (CUE) Stock Price

Cue Biopharma Price

NASDAQ·CLOSED
26.10USD-1.02 (-3.83 %)
Market closed

Over the last 7 years Cue Biopharma grew revenue by 57.5% annually, reaching 27.47 M USD. For Cue Biopharma, the net margin of -96.9% is up versus -295.6% a few years ago. The consensus 12-month price target for Cue Biopharma is 5.10 USD, about 80.5% below where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus. Cue Biopharma's share price has gained 10.1% over the last twelve months. The stock trades about 392% above its 52-week low.

Cue Biopharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cue Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cue Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cue Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cue Biopharma Stock Price History
DateCue Biopharma Price
8/10/202626.10 USD
8/7/202627.12 USD
8/6/202627.01 USD
8/5/202627.06 USD
8/4/202627.14 USD
8/3/202626.87 USD
7/31/202626.84 USD
7/30/202630.40 USD
7/29/202629.30 USD
7/27/202632.50 USD
7/23/202633.09 USD
7/22/202634.20 USD
7/21/202633.46 USD
7/20/202630.95 USD
7/17/202631.16 USD
7/16/202627.79 USD
7/15/202628.49 USD
7/14/202631.28 USD
7/13/202630.92 USD
7/10/202636.78 USD
7/9/202636.51 USD
7/8/202632.66 USD
7/7/202633.39 USD
7/6/202628.29 USD
7/2/202628.26 USD
7/1/202628.34 USD
6/30/202631.56 USD
6/29/202630.43 USD
6/26/202625.39 USD
6/25/202625.54 USD
6/24/202626.01 USD
6/23/202626.90 USD
6/22/202630.58 USD
6/18/202628.46 USD
6/17/202626.73 USD
6/16/202623.89 USD
6/15/202625.80 USD
6/12/202624.53 USD
6/11/202627.09 USD
6/10/202627.86 USD
6/9/202630.44 USD
6/8/202629.08 USD
6/5/202629.46 USD
6/4/202629.64 USD
6/3/202626.91 USD
6/2/202628.62 USD
6/1/202624.07 USD
5/29/202621.90 USD
5/28/202622.64 USD
5/27/202620.43 USD
5/26/202620.03 USD
5/22/202621.47 USD
5/21/202620.10 USD
5/20/202620.43 USD
5/19/202620.30 USD
5/18/202621.38 USD
5/15/202623.01 USD
5/14/202625.33 USD
5/13/202629.47 USD
5/12/202629.26 USD
5/11/202631.32 USD
5/8/202635.00 USD
5/7/202635.73 USD
5/6/202633.98 USD
5/5/202634.94 USD
5/4/202629.85 USD
5/1/202630.42 USD
4/30/202614.74 USD
4/29/202613.00 USD
4/28/202612.46 USD
4/27/202617.93 USD
4/24/202617.70 USD
4/23/202616.63 USD
4/22/202617.40 USD
4/21/202620.10 USD
4/20/202625.49 USD
4/17/202618.19 USD
4/16/202618.46 USD
4/15/202621.73 USD
4/14/202613.14 USD
4/13/202614.17 USD
4/10/202615.06 USD
4/9/20268.79 USD
4/8/20268.21 USD
4/7/20265.65 USD
4/6/20265.31 USD
4/2/20265.40 USD
4/1/20266.08 USD
3/31/20266.90 USD
3/30/20266.78 USD
3/27/20267.18 USD
3/26/20267.53 USD
3/25/20267.93 USD
3/24/20267.65 USD
3/23/20267.99 USD
3/20/20267.97 USD
3/19/20267.93 USD
3/18/20267.93 USD
3/17/20268.15 USD
3/16/20269.35 USD
3/13/20268.51 USD
3/12/20269.13 USD
3/11/20269.75 USD
3/10/20269.30 USD
3/9/20269.03 USD
3/6/20268.99 USD
3/5/20268.63 USD
3/4/20269.07 USD
3/3/20268.89 USD
3/2/20268.47 USD
2/27/20268.40 USD
2/26/20268.64 USD
2/25/20268.50 USD
2/24/20268.45 USD
2/23/20268.43 USD
2/20/20268.54 USD
2/19/20268.80 USD
2/18/20268.91 USD
2/17/20268.73 USD
2/13/20269.20 USD
2/12/20269.00 USD
2/11/20269.65 USD
2/10/202610.12 USD
2/9/20269.69 USD
2/6/20269.60 USD
2/5/20269.48 USD
2/4/20269.28 USD
2/3/20269.90 USD
2/2/202610.20 USD
1/30/202610.04 USD
1/29/202610.84 USD
1/28/202611.13 USD
1/27/202611.72 USD
1/26/202610.93 USD
1/23/202611.40 USD
1/22/202610.94 USD
1/21/202611.27 USD
1/20/20268.97 USD
1/16/20269.06 USD
1/15/20268.31 USD
1/14/202610.23 USD
1/13/202610.52 USD
1/12/202610.35 USD
1/9/202610.82 USD
1/8/202611.79 USD
1/7/202611.61 USD
1/6/202611.01 USD
1/5/202611.48 USD
1/2/202610.12 USD
12/31/20259.16 USD
12/30/20259.07 USD
12/29/20258.31 USD
12/26/20259.74 USD
12/24/20257.23 USD
12/23/20257.30 USD
12/22/20257.61 USD
12/19/20258.05 USD
12/18/202510.26 USD
12/17/202512.00 USD
12/16/202512.30 USD
12/15/202513.88 USD
12/12/202514.61 USD
12/11/202514.80 USD
12/10/202514.32 USD
12/9/202514.84 USD
12/8/202515.85 USD
12/5/202516.46 USD
12/4/202516.59 USD
12/3/202516.83 USD
12/2/202517.13 USD
12/1/202517.85 USD
11/28/202518.90 USD
11/26/202518.77 USD
11/25/202518.27 USD
11/24/202517.71 USD
11/21/202517.85 USD
11/20/202516.22 USD
11/19/202517.41 USD
11/18/202517.40 USD
11/17/202517.22 USD
11/14/202518.90 USD
11/13/202518.59 USD
11/12/202520.03 USD
11/11/202520.49 USD
11/10/202520.43 USD
11/7/202521.04 USD
11/6/202521.48 USD
11/5/202522.00 USD
11/4/202521.64 USD
11/3/202521.53 USD
10/31/202523.03 USD
10/30/202520.98 USD
10/29/202520.70 USD
10/28/202522.13 USD
10/27/202523.11 USD
10/24/202523.56 USD
10/23/202523.41 USD
10/22/202522.96 USD
10/21/202524.75 USD
10/20/202524.62 USD
10/17/202523.89 USD
10/16/202523.70 USD
10/15/202523.55 USD
10/14/202523.92 USD
10/13/202524.45 USD
10/10/202523.87 USD
10/9/202527.79 USD
10/8/202525.74 USD
10/7/202522.57 USD
10/6/202521.83 USD
10/3/202521.87 USD
10/2/202521.56 USD
10/1/202521.71 USD
9/30/202521.56 USD
9/29/202521.58 USD
9/26/202521.29 USD
9/25/202520.70 USD
9/24/202521.24 USD
9/23/202521.29 USD
9/22/202521.12 USD
9/19/202520.16 USD
9/18/202521.90 USD
9/17/202521.67 USD
9/16/202522.29 USD
9/15/202522.20 USD
9/12/202522.25 USD
9/11/202522.97 USD
9/10/202522.86 USD
9/9/202523.13 USD
9/8/202523.31 USD
9/5/202523.40 USD
9/4/202523.55 USD
9/3/202523.79 USD
9/2/202523.79 USD
8/29/202523.41 USD
8/28/202524.05 USD
8/27/202524.77 USD
8/26/202525.20 USD
8/25/202524.55 USD
8/22/202524.78 USD
8/21/202524.34 USD
8/20/202524.25 USD
8/19/202524.48 USD
8/18/202524.56 USD
8/15/202524.78 USD
8/14/202523.70 USD
8/13/202524.31 USD
8/12/202523.70 USD
Access this data via the Eulerpool API
Get Free API Key

Cue Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
1.25 M USD
-53.23 M USD
-53.01 M USD
Jan 1, 2023
5.49 M USD
-52.15 M USD
-50.73 M USD
Jan 1, 2024
9.29 M USD
-41.50 M USD
-40.67 M USD
Jan 1, 2025
27.47 M USD
-26.52 M USD
-26.60 M USD
Jan 1, 2026 (e)
12.80 M USD
-12.64 M USD
-522.83 M USD
Jan 1, 2027 (e)
1.00 M USD
-987,468.00 USD
-744.09 M USD
Jan 1, 2028 (e)
1.00 M USD
-987,468.00 USD
-1.20 B USD
Jan 1, 2029 (e)
1.00 M USD
-987,468.00 USD
-1.23 B USD

Cue Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 3:15 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e
–––1.003.003.0014.001.005.009.0027.0012.001.001.001.00
––––200.00–366.67-92.86400.0080.00200.00-55.56-91.67––
–––-2,700.00100.00-1,000.00100.00100.00-640.00100.00100.00100.00100.00100.00100.00
27.0027.0027.00-27.003.00-30.0014.001.00-32.009.0027.0012.001.001.001.00
-1.00-7.00-23.00-38.00-36.00-45.00-43.00-53.00-52.00-41.00-26.00-12.00–––
–––-3,800.00-1,200.00-1,500.00-307.14-5,300.00-1,040.00-455.56-96.30-100.00–––
–-0.01-0.02-0.04-0.04-0.04-0.04-0.05-0.05-0.04-0.03-0.52-0.74-1.20-1.23
–600.00228.5765.22-5.2622.22–20.45-5.66-20.00-35.001,907.6942.5361.831.99
3.680.690.690.690.800.991.051.311.572.473.683.683.683.683.68
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cue Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cue Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cue Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cue Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cue Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cue Biopharma stock margins

The Cue Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cue Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cue Biopharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-292.56 %
-295.56 %
Jan 1, 2022
100.00 %
-4,275.10 %
-4,257.83 %
Jan 1, 2023
-593.93 %
-949.89 %
-924.10 %
Jan 1, 2024
100.00 %
-446.86 %
-437.97 %
Jan 1, 2025
100.00 %
-96.56 %
-96.85 %
Jan 1, 2026 (e)
100.00 %
-98.75 %
-4,084.64 %
Jan 1, 2027 (e)
100.00 %
-98.75 %
-74,409.30 %
Jan 1, 2028 (e)
100.00 %
-98.75 %
-120,472.19 %

Cue Biopharma Stock Revenue, EBIT, Earnings per Share

The Cue Biopharma earnings per share therefore indicates how much revenue Cue Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
14.22 USD
-41.61 USD
-42.04 USD
Jan 1, 2022
0.95 USD
-40.76 USD
-40.60 USD
Jan 1, 2023
3.49 USD
-33.18 USD
-32.28 USD
Jan 1, 2024
3.75 USD
-16.77 USD
-16.44 USD
Jan 1, 2025
7.46 USD
-7.20 USD
-7.22 USD
Jan 1, 2026 (e)
0.16 USD
-3.43 USD
-6.64 USD
Jan 1, 2027 (e)
0.01 USD
-0.27 USD
-9.45 USD
Jan 1, 2028 (e)
0.01 USD
-0.27 USD
-15.30 USD

Cue Biopharma business model & stock analysis

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years.

Cue Biopharma SWOT Analysis

Strengths

Cue Biopharma Inc possesses several strengths that contribute to its success in the biopharmaceutical industry. These strengths include:

  • Strong Intellectual Property (IP) portfolio, providing a competitive advantage in the market.
  • Experienced and skilled research and development (R&D) team, driving innovation and product development.
  • Partnerships and collaborations with reputable pharmaceutical companies, expanding its reach and resources.
  • Advanced technology platforms and scientific expertise in immuno-oncology, enabling the development of novel therapies.

Weaknesses

Despite its strengths, Cue Biopharma Inc also faces certain weaknesses that may hinder its growth prospects. These weaknesses include:

  • Reliance on external funding sources, which may pose financial risks and limitations.
  • Limited product pipeline, potentially impacting revenue generation and long-term sustainability.
  • Dependence on key collaborations and partnerships, making the company vulnerable to shifts in those relationships.

Opportunities

Cue Biopharma Inc can take advantage of several opportunities to further enhance its position in the industry. These opportunities include:

  • Increasing demand for immuno-oncology therapies worldwide, providing a growing market.
  • Expansion into new geographic regions and markets, widening its customer base.
  • Collaborations with academic institutions and research organizations, fostering knowledge exchange and accelerating research progress.
  • Investment in additional R&D capabilities, allowing for the development of a more diverse product portfolio.

Threats

Cue Biopharma Inc should be aware of potential threats that could impede its progress and success. These threats include:

  • Intense competition from other biopharmaceutical companies, leading to market saturation and pricing pressures.
  • Stringent regulations and approval processes within the pharmaceutical industry, causing delays and increased costs.
  • The possibility of a failure in clinical trials or product development, resulting in reputational damage and financial setbacks.
  • Evolving healthcare policies and reimbursement systems, influencing the market access and pricing of its products.

Cue Biopharma Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Cue Biopharma Employees
Details
Date
Cue Biopharma Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Cue Biopharma Segments

Cue Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cue Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Cue Biopharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cue Biopharma shares outstanding

The number of shares of Cue Biopharma was 3.68 M in 2025. This indicates how many shares Cue Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
1.05 M Stocks
Jan 1, 2022
1.31 M Stocks
Jan 1, 2023
1.57 M Stocks
Jan 1, 2024
2.47 M Stocks
Jan 1, 2025
3.68 M Stocks
Jan 1, 2026 (e)
3.68 M Stocks
Jan 1, 2027 (e)
3.68 M Stocks
Jan 1, 2028 (e)
3.68 M Stocks

Current Cue Biopharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
83.33 % (5)
Hold
16.67 % (1)
Sell
0.00 % (0)
12M Price Target
5.10
Last Price
26.10
Currency
USD
12M Return Potential
-80.46 %
LTM Return
0 %

Cue Biopharma Analyst Rating Actions

DateFirmActionRatingReliability
4/2/2025
Citizens Capital Markets
Citizens Capital Markets
MaintainedMarket Outperform–
8/20/2024
Stifel
Stifel
MaintainedBuy–
7/26/2024
Piper Sandler
Piper Sandler
MaintainedOverweight51
7/26/2024
JMP Securities
JMP Securities
MaintainedMarket Outperform–
4/9/2024
Stifel
Stifel
MaintainedBuy–
4/9/2024
Oppenheimer
Oppenheimer
MaintainedOutperform65
4/3/2024
Piper Sandler
Piper Sandler
MaintainedOverweight51
11/6/2023
Piper Sandler
Piper Sandler
MaintainedOverweight51
6/15/2023
Stifel
Stifel
MaintainedBuy–
5/15/2023
JMP Securities
JMP Securities
MaintainedOutperform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Cue Biopharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/18/2026-1.71USD-3.03 MUSD-2026 Q2
5/12/2026-0.11USD-2.53 MUSD-2026 Q1
3/24/2026-0.10USD-2.53 MUSD-2025 Q4
8/12/2025-0.14USD-2.42 MUSD-2025 Q2
11/12/2024-0.19USD-1.53 MUSD-2024 Q3
5/7/2024-0.27USD-1.18 MUSD-2024 Q1
3/19/2024-0.28USD-1.73 MUSD-2023 Q4
11/13/2023-0.38USD-47,958.00USD-2023 Q3
8/2/2023-0.40USD-521,202.00USD-2023 Q2
5/8/2023-0.34USD-1.04 MUSD-2023 Q1

EESG©

Eulerpool ESG Scorecard© for the Cue Biopharma stock

49/100
52
Environment
54
Social
40
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cue Biopharma shareholder structure

% Name
8.66036%
Bleichroeder LP
Bleichroeder LP
4.23120%
Catalytic Wealth RIA, LLC
Catalytic Wealth RIA, LLC
4.04794%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.87906%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
0.60770%
Robertson Stephens Wealth Management, LLC
Robertson Stephens Wealth Management, LLC
0.56717%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.

Cue Biopharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
9.99%
Bleichroeder LP
Bleichroeder LP
SEC ↗
8.00%
Wilmot B. Harkey
Wilmot B. Harkey
SEC ↗
8.00%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
SEC ↗
8.00%
Daniel Mack
Daniel Mack
SEC ↗
7.60%
Peter A. Appel
Peter A. Appel
SEC ↗
5.60%
David Greenspan
David Greenspan
SEC ↗
5.60%
Slate Path Master Fund LP
Slate Path Master Fund LP
SEC ↗
5.60%
Jades GP, LLC
Jades GP, LLC
SEC ↗
5.23%
STATE STREET CORPORATION
STATE STREET CORPORATION
SEC ↗
4.99%
Mark E. Strome
Mark E. Strome
SEC ↗

Cue Biopharma Executives and Management Board

11 members · avg. age 64 · 18 % women

ML

Mr. Matteo Levisetti (56)

Chief Medical Officer

1.19 M USD

Management

CS

Mr. Colin Sandercock (68)

Senior Vice President, General Counsel, Secretary

625,514.00 USD
UA

Dr. Usman Azam (57)

President, Chief Executive Officer, Director · since 2025

–
DB

Dr. Daniel Baker (74)

Interim Chief Development Officer

–
LW

Ms. Lucinda Warren (56)

Chief Business officer

–

Board of Directors

PK

Dr. Peter Kiener (72)

Independent Director

219,750.00 USD
FM

Dr. Frank Morich (71)

Independent Chairman of the Board

115,887.00 USD
PV

Mr. Patrick Verheyen (65)

Independent Director

103,250.00 USD
PG

Dr. Pamela Garzone (70)

Independent Director

95,750.00 USD
JB

Mr. Jill Broadfoot

Director

–
PS

Mr. Pasha Sarraf (55)

Independent Director

–

Cue Biopharma Supply Chain

Cue Biopharma Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Merck & Co
Supplier·Customer·Pharmaceuticals·US
-0.27
-0.85
-0.74
-0.68
-0.46
-0.40
2
Catalent
Supplier·Customer·Pharmaceuticals·US
0.20
-0.13
0.67
0.82
0.83
-0.19

Frequently asked questions about Cue Biopharma

Cue Biopharma Inc is a biotechnology company with a unique business model. It focuses on developing a novel class of biologics called immuno-modulatory proteins (CMPs) to treat a wide range of cancers and autoimmune diseases. By leveraging its Cue Biologics platform, the company aims to engineer CMPs that can selectively modulate immune responses, enhancing the body's ability to fight diseases effectively. Cue Biopharma Inc's business model revolves around creating innovative therapies that leverage the power of the immune system, offering a promising approach in the field of precision medicine.

Cue Biopharma Inc is primarily active in the biotechnology industry.

The main competitors of Cue Biopharma Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Eli Lilly and Company, and Merck & Co. These companies also operate in the field of immunotherapy and targeted biologics, which aligns with Cue Biopharma's focus on developing novel biologic therapies for various diseases. Through their extensive research and development efforts, these competitors strive to provide innovative treatments that can effectively address the unmet medical needs of patients.

Cue Biopharma Inc is a biopharmaceutical company founded in 2015. The company focuses on developing innovative immunotherapy drugs for the treatment of various cancers and autoimmune diseases. Cue Biopharma combines insights from immunology and protein engineering to create drugs that enhance the body's immune response against these diseases. With a strong emphasis on precision medicine, Cue Biopharma aims to address the limitations of current treatment options by developing therapies that target specific disease-causing molecules. Through its cutting-edge platform, the company is committed to advancing the field of immunotherapy and improving patient outcomes.

Cue Biopharma Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in October 2017, raising $66.5 million. Cue Biopharma Inc has advanced multiple programs and entered into several strategic partnerships. It has collaborated with Merck under a multi-year collaboration to develop a potential treatment for cancer. Furthermore, Cue Biopharma Inc has leveraged its proprietary platform technology, Immuno-STAT, to create a pipeline of potential immunotherapies targeting various diseases. The company has made remarkable progress in the field of biopharmaceuticals, positioning itself as a leader in the development of innovative immunotherapeutics.

Cue Biopharma Inc is primarily present in the United States.

Cue Biopharma Inc represents values of innovation, dedication, and collaboration in the biopharmaceutical industry. The company strives to develop novel and advanced immunotherapies to address critical unmet needs for patients. With a corporate philosophy centered around precision medicine and immuno-oncology, Cue Biopharma is committed to harnessing the power of the immune system to fight against cancer and other diseases. By leveraging its innovative Immuno-STAT™ platform, the company aims to create highly targeted therapies that can revolutionize the treatment landscape. Cue Biopharma's focus on cutting-edge science and strategic partnerships reflects its dedication to improving patient outcomes and advancing the field of immunotherapy.

Analysts currently set an average price target of 5.10 USD for the Cue Biopharma stock (median: 5.10 USD), implying -80.5 % versus the latest price. The consensus is based on 6 analyst ratings.

Cue Biopharma Analyst Price Targets 2026

6 analysts currently rate the Cue Biopharma stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cue Biopharma to generate revenue of 12.80 M USD and earnings per share of -141.93 USD.

Cue Biopharma Analyst Price Targets 2026

Converted at the current exchange rate, the Cue Biopharma share trades at 22.60 EUR (26.10 USD).

The Cue Biopharma share (CUE) is listed on 3 stock exchanges, including: NASDAQ (CUE), Frankfurt (1UC.F), München (1UC.MU).

Cue Biopharma Inc is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. The business model of Cue Biopharma Inc is based on the use of immunotherapies targeting the body's immune system to fight cancer and autoimmune diseases. The company utilizes a unique platform called Immuno-STATs (Signal Transducer and Activator of Transcription Proteins) to create artificial proteins specifically targeting T cells in the immune system. These proteins can then be used to selectively activate the immune system and attack diseased cells in the body. Cue Biopharma Inc focuses on developing tailored immunotherapies customized to each patient's individual needs. The company is divided into several business areas, including research and development, clinical trials, and commercial production. Cue Biopharma Inc collaborates closely with leading researchers and scientists in the field of immunology to leverage the latest advancements and technologies. Cue Biopharma Inc currently offers several products, including CUE-101, CUE-102, and CUE-103. CUE-101 is an immunotherapeutic currently in phase 1 clinical trial for the treatment of HPV-associated cancer. CUE-102 and CUE-103 are still in preclinical development but have shown promising results in studies. CUE-103 is primarily intended for the treatment of autoimmune diseases such as type 1 diabetes and rheumatoid arthritis. The company is committed to continuously researching and developing better and more targeted immunotherapies to help millions of people worldwide. In summary, Cue Biopharma Inc is an innovative company specializing in the development of tailored immunotherapies for the treatment of cancer and autoimmune diseases. The company utilizes a unique technology to selectively activate the immune system and attack diseased cells in the body. Through close collaboration with leading researchers and scientists in the field of immunology, as well as ongoing research and development, the company aims to develop increasingly better and more effective therapies.

The expected revenue of Cue Biopharma is 12.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cue Biopharma is -522.83 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cue Biopharma is currently -0.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cue Biopharma stock.

The price-to-sales ratio (P/S) of Cue Biopharma is currently 7.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cue Biopharma stock.

The Eulerpool Quality Score for Cue Biopharma is 4/10.

The ISIN of Cue Biopharma is US22978P1066. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cue Biopharma is A2JAT5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cue Biopharma is CUE. The ticker symbol is used to trade Cue Biopharma shares on the stock exchange.

Cue Biopharma paid dividends every year for the past 0 years.

Cue Biopharma is assigned to the 'Health' sector.

The dividends of Cue Biopharma are distributed in USD.

All fundamentals and in-depth analysis of Cue Biopharma

Our stock analysis for Cue Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cue Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cue Biopharma Stock
Cue Biopharma Revenue→
Cue Biopharma Stock
Cue Biopharma Net Income→
Cue Biopharma Stock
Cue Biopharma P/E→
Cue Biopharma Stock
Cue Biopharma P/S→
Cue Biopharma Stock
Cue Biopharma EBIT→
Cue Biopharma Stock
Cue Biopharma Dividend→
Cue Biopharma Stock
Cue Biopharma Directors Dealings→
Cue Biopharma Stock
Cue Biopharma Stocks→
Cue Biopharma Stock
Cue Biopharma Market capitalization→
Cue Biopharma Stock
Cue Biopharma Debt→
Cue Biopharma Stock
Cue Biopharma Liabilities→
Cue Biopharma Stock
Cue Biopharma Equity→
Cue Biopharma Stock
Cue Biopharma AAQS→
Cue Biopharma Stock
Cue Biopharma Employees→
Cue Biopharma Stock
Cue Biopharma ROE→
Cue Biopharma Stock
Cue Biopharma ROA→
Cue Biopharma Stock
Cue Biopharma ROCE→
Cue Biopharma Stock
Cue Biopharma News→
Cue Biopharma Stock
Cue Biopharma Analyst Price Targets→

Health Stocks

Cue HealthCUCCullinan TherapeuticsCU Medical SystemsCumberland PharmaceuticalsCTT Pharmaceutical HoldingsCuoripsCTC BioCuprina Holdings (Cayman)CStone PharmaceuticalsCuracle CoCSPC Pharmaceutical GroupAll Stocks A–Z →